The impact of IDH mutations on prognosis is uncertain, with some recent studies reporting an improved outcome [33, 64, 65], and others reporting an inferior outcome to IDH wildtype AML [65–67]. The gene discussed is IDH1; the disease is acute myeloid leukemia.